
TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 7.180824 | 24.8557424714 | 28.89 | 36.94 | 28.17 | 4199640 | 32.61293544 | CS |
4 | 4.570824 | 14.510552381 | 31.5 | 36.94 | 28.17 | 2236586 | 31.99646029 | CS |
12 | 3.130824 | 9.50462659381 | 32.94 | 36.94 | 27.24 | 2327655 | 31.23135288 | CS |
26 | 13.980824 | 63.2902851969 | 22.09 | 36.94 | 21.11 | 3026996 | 28.24659843 | CS |
52 | 18.140824 | 101.175817066 | 17.93 | 36.94 | 12.93 | 3060387 | 22.97266305 | CS |
156 | 26.720824 | 285.784213904 | 9.35 | 36.94 | 3.48 | 3863153 | 15.71032612 | CS |
260 | 22.170824 | 159.502330935 | 13.9 | 56.74 | 3.48 | 3034182 | 18.30325495 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.